PPT1 and cancer: Accordingly, if autophagy cargo receptors are secreted during DC661-mediated lysosomal inhibition, one can speculate that these proteins may serve as noninvasive biomarkers to monitor the efficacy of PPT1 inhibition during cancer treatment.